CREYON
Live / Applied — Statement of use — processing complete, to examiner (as of 29 Mar 2026)
What this means for you
Not registered yet, but its 23 Jul 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90846005
- Mark type
- Stylized text
- Filed
- 23 Jul 2021
- Published for opposition
- 24 Jan 2023
- Attorney of record
- Emilia F. Cannella
Goods and services
- Class 042 — Scientific and technological services: Medical and scientific research in the field of Oligonucleotide-Based Medicines; Oligonucleotide-Based drug development services; engineering and chemical synthesis of oligonucleotide-based medicines and their building blocks and delivery technologies; engineering and chemical synthesis of oligonucleotide therapeutics and their building blocks and delivery technologies; experimental assessment of pharmacological and chemical properties of oligonucleotide-base medicines in the nature of pharmaceutical research and development
Owner
- Creyon Bio, Inc., San Diego, CA, US
- Creyon Bio, Inc., San Diego, CA, US
Prosecution history
- 29 Mar 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 23 Mar 2026 — USE AMENDMENT FILED
- 23 Mar 2026 — TEAS STATEMENT OF USE RECEIVED
- 06 Feb 2026 — SOU EXTENSION 5 GRANTED
- 17 Sept 2025 — SOU EXTENSION 5 FILED
- 06 Feb 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 18 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Mar 2025 — SOU EXTENSION 4 GRANTED
- 14 Mar 2025 — SOU EXTENSION 4 FILED
- 14 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 06 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Sept 2024 — SOU EXTENSION 3 GRANTED
- 06 Sept 2024 — SOU EXTENSION 3 FILED
- 06 Sept 2024 — SOU TEAS EXTENSION RECEIVED